News
![Why Roche Holdings Stock Popped Today: https://g.foolcdn.com/editorial/images/772667/lady-scientist-in-lab-coat-and-goggles-pours-blue-liquid-from-a-test-tube-into-a-beaker.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWx5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4048a34730b439d64cc07fc13363f00e9a6c117/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/lady-scientist-in-lab-coat-and-goggles-pours-blue-liquid-from-a-test-tube-into-a-beaker.jpg?locale=us)
Why Roche Holdings Stock Popped Today
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains.
Roche announced this morning that the U.S
![Vertex Pharmaceuticals: Buy, Sell, or Hold?: https://g.foolcdn.com/editorial/images/772095/doctor-giving-a-patient-medication.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTF5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5643f6c7793ad92b6248d5e41eba50d88f99815b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-giving-a-patient-medication.jpg?locale=us)
Vertex Pharmaceuticals: Buy, Sell, or Hold?
Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now
![Is Amgen Stock a Buy?: https://g.foolcdn.com/editorial/images/772093/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTl5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e96df81f452955930afc976feaa2378ba180e37f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=us)
Is Amgen Stock a Buy?
Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to
![Got $200? 2 Healthcare Stocks to Buy and Hold Forever.: https://g.foolcdn.com/editorial/images/772266/doctor-and-patient-in-a-hospital-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHh4YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--71a853610c482c325dc5fef86f8602f72e40acbb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-in-a-hospital-room.jpg?locale=us)
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
There are plenty of things to buy with $200. But what about investing in a company that can grow your capital for years? Though some people believe they need millions, or at least thousands, to
![QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay: https://mms.businesswire.com/media/20240410125315/en/2093757/5/7600_front_transparent.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXh3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a83d4c4c7386f35bb60ef136bcb7048b94c29c82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/7600_front_transparent.jpg?locale=us)
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a
![Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlZ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5103757f3bbf4c60c976668f7e4df4a6b339440b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-agreeing-on-a-deal.jpg?locale=us)
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of
![Where Will Pfizer Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/772094/businessperson-giving-a-presentation.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc861e37c2dbaaf6c49c15c3c7861f9b714060b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessperson-giving-a-presentation.jpg?locale=us)
Where Will Pfizer Stock Be in 10 Years?
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have
![This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjF2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--faa9f1a53d2c795443e1ff98fce9326f8090e204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive
![2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/772254/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlJ2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a72e2b15536f1dcd376d4a20375f305795a38207/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=us)
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in
![Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.: https://g.foolcdn.com/editorial/images/771899/gettyimages-1429005115.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1J1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--acaf3fe75d702db5a38fcc159b5e0b5de99e2e4d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1429005115.jpg?locale=us)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.
![Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?: https://g.foolcdn.com/editorial/images/772136/scientists-in-a-lab-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXB1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f456820945b8846d2951add1fca2e38d2aaf2514/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-in-a-lab-smiling.jpg?locale=us)
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made
![3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/772112/investor-stock-charts-laptop-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODl1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--02c9a5773141514117407f596c8847b99bc4980a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stock-charts-laptop-getty.jpg?locale=us)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions
![Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All: https://mms.businesswire.com/media/20240408083962/en/2089996/5/2023_Humana_Impact_Report_Summary_HD.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUZ1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c9ca9543646450dee04de7a703b2b2e354bfd06e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/2023_Humana_Impact_Report_Summary_HD.jpg?locale=us)
Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, announced the release of its 2023 Impact Report, which includes details on the company’s continued commitment
![2 Growth Stocks to Buy Hand Over Fist in April: https://g.foolcdn.com/editorial/images/771856/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0Z1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6898c1bb4bf7d94cf3c855c5465cc65312d71cf0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=us)
2 Growth Stocks to Buy Hand Over Fist in April
Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.
![This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market: https://g.foolcdn.com/editorial/images/771902/surprised-young-woman-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXB0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2bda56627595ded11d575e9071dc7e5e3c15a18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/surprised-young-woman-laptop.jpg?locale=us)
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
Two adages capture the dilemma investors face when they consider buying a beaten-down stock:
These well-known sayings seem to be contradictory. However, they're not when taken in the correct
![2 Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/771565/doctor-in-consultation-with-a-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFJ0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--048d163088340f31cdbe08e9e7447633d04e0755/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-in-consultation-with-a-patient.jpg?locale=us)
2 Dividend Stocks to Buy and Hold Forever
Dividends can provide a steady stream of income to shareholders, but only if the dividend-paying company maintains or increases its payouts over the years. Unfortunately, not every dividend payer is
![UnitedHealth's 6.4% Drop Brings Microsoft This Much Closer to Becoming the Most Important Stock in the Dow Jones Industrial Average: https://g.foolcdn.com/editorial/images/771795/gettyimages-1340542435-1201x511-15253f2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFZ0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4031bbc7679750000f69de38d68c08f96be77022/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1340542435-1201x511-15253f2.jpg?locale=us)
UnitedHealth's 6.4% Drop Brings Microsoft This Much Closer to Becoming the Most Important Stock in the Dow Jones Industrial Average
Microsoft (NASDAQ: MSFT) is currently the only company worth over $3 trillion. That makes it the most heavily weighted stock in both the S&P 500 and the Nasdaq Composite, but not the Dow Jones
![Is Zscaler a Buy on the Dip?: https://g.foolcdn.com/editorial/images/771714/cybersecurity-protection-lock-key.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenh0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f2dddfc55bae3078d844cf77a0777144ce363f94/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cybersecurity-protection-lock-key.jpg?locale=us)
Is Zscaler a Buy on the Dip?
Cybersecurity has been one of the hottest investment sectors in recent years. Given the number of high-profile cybersecurity attacks and breaches, this probably should not be surprising. For
![2 Biotech Stocks to Buy Hand Over Fist in April: https://g.foolcdn.com/editorial/images/771546/patient-talking-with-a-physician.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWRzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e4cceab45cfe03bb57a5899d2a4c79d294c1a854/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-talking-with-a-physician.jpg?locale=us)
2 Biotech Stocks to Buy Hand Over Fist in April
The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure
![3 No-Brainer Dividend Stocks to Buy in April: https://g.foolcdn.com/editorial/images/771862/hands-behind-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3RzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0bc9db6d00e54978c617a1b048fdcf5e4e33e878/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/hands-behind-head.jpg?locale=us)
3 No-Brainer Dividend Stocks to Buy in April
Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like
![Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul: https://g.foolcdn.com/editorial/images/771624/dna-sequencing-genome-science-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVpzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b3344d1f2ba4a444c86102ed51b2e8a93ba38463/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-sequencing-genome-science-lab.jpg?locale=us)
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
While no one can say with absolute certainty what the market will or won't do in 2024, finding great stocks that have the power to stand the test of time in your portfolio doesn't have to be
![Why Humana Stock Fell 10.9% This Week: https://g.foolcdn.com/editorial/images/771845/doctor-seeing-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTlyYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b77ce84e1bbc23ae703d0857d772fa356e27202e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-seeing-elderly-patient.jpg?locale=us)
Why Humana Stock Fell 10.9% This Week
Shares of Humana (NYSE: HUM) are down 11.8% so far this week as of Thursday's close, according to data provided by S&P Global Market Intelligence, after the U.S. Centers for Medicare and Medicaid
![Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2hyYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a25779b49e4738fad49fc7ef763c7239b98947bd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-talking-to-patient.jpg?locale=us)
Should You Sell This Stock Following a Regulatory Roadblock?
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its
![QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test: https://mms.businesswire.com/media/20240401748874/en/2086245/5/1542601_QV_UC_COVID-19_2T_Angle01.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3BvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9ae16133c13a2fc034c0b726b0fe6e0e20fc38ab/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/1542601_QV_UC_COVID-19_2T_Angle01.jpg?locale=us)
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test. This clearance allows